325 related articles for article (PubMed ID: 17346176)
1. Adenosine metabolism in Toxoplasma gondii: potential targets for chemotherapy.
el Kouni MH
Curr Pharm Des; 2007; 13(6):581-97. PubMed ID: 17346176
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.
Kim YA; Sharon A; Chu CK; Rais RH; Al Safarjalani ON; Naguib FN; el Kouni MH
Biochem Pharmacol; 2007 May; 73(10):1558-72. PubMed ID: 17306769
[TBL] [Abstract][Full Text] [Related]
3. 7-Deaza-6-benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities.
Al Safarjalani ON; Rais RH; Kim YA; Chu CK; Naguib FN; el Kouni MH
Biochem Pharmacol; 2008 Oct; 76(8):958-66. PubMed ID: 18755159
[TBL] [Abstract][Full Text] [Related]
4. New antibacterials for the treatment of toxoplasmosis; a patent review.
Rodriguez JB; Szajnman SH
Expert Opin Ther Pat; 2012 Mar; 22(3):311-33. PubMed ID: 22404108
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of adenosine kinase from Toxoplasma gondii at 1.8 A resolution.
Cook WJ; DeLucas LJ; Chattopadhyay D
Protein Sci; 2000 Apr; 9(4):704-12. PubMed ID: 10794412
[TBL] [Abstract][Full Text] [Related]
6. Hydroxylamine and Carboxymethoxylamine Can Inhibit
Li J; Guo H; Galon EM; Gao Y; Lee SH; Liu M; Li Y; Ji S; Jia H; Xuan X
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907178
[No Abstract] [Full Text] [Related]
7. Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
Deng Y; Wu T; Zhai SQ; Li CH
Eur J Med Chem; 2019 Dec; 183():111711. PubMed ID: 31585276
[TBL] [Abstract][Full Text] [Related]
8. Bicyclic azetidines target acute and chronic stages of Toxoplasma gondii by inhibiting parasite phenylalanyl t-RNA synthetase.
Radke JB; Melillo B; Mittal P; Sharma M; Sharma A; Fu Y; Uddin T; Gonse A; Comer E; Schreiber SL; Gupta AK; Chatterjee AK; Sibley LD
Nat Commun; 2022 Jan; 13(1):459. PubMed ID: 35075105
[TBL] [Abstract][Full Text] [Related]
9. Invasion and egress by the obligate intracellular parasite Toxoplasma gondii: potential targets for the development of new antiparasitic drugs.
Lavine MD; Arrizabalaga G
Curr Pharm Des; 2007; 13(6):641-51. PubMed ID: 17346179
[TBL] [Abstract][Full Text] [Related]
10. 6-Benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities.
Rais RH; Al Safarjalani ON; Yadav V; Guarcello V; Kirk M; Chu CK; Naguib FN; el Kouni MH
Biochem Pharmacol; 2005 May; 69(10):1409-19. PubMed ID: 15857605
[TBL] [Abstract][Full Text] [Related]
11. Dichloroacetate and Pyruvate Metabolism: Pyruvate Dehydrogenase Kinases as Targets Worth Investigating for Effective Therapy of Toxoplasmosis.
Ferrarini MG; Nisimura LM; Girard RMBM; Alencar MB; Fragoso MSI; Araújo-Silva CA; Veiga AA; Abud APR; Nardelli SC; Vommaro RC; Silber AM; France-Sagot M; Ávila AR
mSphere; 2021 Jan; 6(1):. PubMed ID: 33408226
[TBL] [Abstract][Full Text] [Related]
12. Targeting
Palencia A; Bougdour A; Brenier-Pinchart MP; Touquet B; Bertini RL; Sensi C; Gay G; Vollaire J; Josserand V; Easom E; Freund YR; Pelloux H; Rosenthal PJ; Cusack S; Hakimi MA
EMBO Mol Med; 2017 Mar; 9(3):385-394. PubMed ID: 28148555
[No Abstract] [Full Text] [Related]
13. Carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase: biological activities and selective toxicities.
Al Safarjalani ON; Rais RH; Kim YA; Chu CK; Naguib FN; El Kouni MH
Biochem Pharmacol; 2010 Oct; 80(7):955-63. PubMed ID: 20541538
[TBL] [Abstract][Full Text] [Related]
14. Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase.
Darling JA; Sullivan WJ; Carter D; Ullman B; Roos DS
Mol Biochem Parasitol; 1999 Sep; 103(1):15-23. PubMed ID: 10514077
[TBL] [Abstract][Full Text] [Related]
15. Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii.
Chaudhary K; Darling JA; Fohl LM; Sullivan WJ; Donald RG; Pfefferkorn ER; Ullman B; Roos DS
J Biol Chem; 2004 Jul; 279(30):31221-7. PubMed ID: 15140885
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and selective toxicity of 6-nitrobenzylthioinosine in Toxoplasma gondii.
el Kouni MH; Guarcello V; Al Safarjalani ON; Naguib FN
Antimicrob Agents Chemother; 1999 Oct; 43(10):2437-43. PubMed ID: 10508021
[TBL] [Abstract][Full Text] [Related]
17. Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.
Kortagere S; Mui E; McLeod R; Welsh WJ
J Comput Aided Mol Des; 2011 May; 25(5):403-11. PubMed ID: 21359560
[TBL] [Abstract][Full Text] [Related]
18. Human toxoplasmosis-Searching for novel chemotherapeutics.
Antczak M; Dzitko K; Długońska H
Biomed Pharmacother; 2016 Aug; 82():677-84. PubMed ID: 27470411
[TBL] [Abstract][Full Text] [Related]
19. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
Liu S; Wu M; Hua Q; Lu D; Tian Y; Yu H; Cheng L; Chen Y; Cao J; Hu X; Tan F
Parasit Vectors; 2020 May; 13(1):242. PubMed ID: 32393321
[TBL] [Abstract][Full Text] [Related]
20. Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.
Murata Y; Sugi T; Weiss LM; Kato K
PLoS One; 2017; 12(6):e0178203. PubMed ID: 28609444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
